Efgartigimod Provides Genuine Benefit For Myasthenia Gravis Disease Overview Efgartigimod, a neonatal Fc receptor inhibitor, has recently received approval for the treatment of myasthenia gravis (MG). This retrospective cohort study systematically evaluated the short- and long-term efficacy of efgartigimod in patients with refractory MG. Sixteen patients with autoimmune acetylcholine receptor MG, who
Tag: chronic autoimmune disease
Pain Intensity In Idiopathic Inflammatory Myopathies And Rheumatic Diseases
Pain Intensity In Idiopathic Inflammatory Myopathies And Rheumatic Diseases Pain management is central to the medical practice of many medical professionals, especially rheumatologists and pain experts. Pain intensity has important implications, as it often indicates the severity of a disease, its prognosis, and the outcome of specific treatments. Also, evidence shows
